Vaccinex, Inc. (VCNX)
Oxford Ledge is still expanding full research coverage of VCNX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Clinical-stage biotech developing SEMA4D-blocking antibodies, primarily pepinemab, for neurodegenerative diseases and cancer through proprietary discovery platforms.
SEC filings
- 10-K Annual financial report with audited statements 2025-04-15
- 8-K Departure/election of directors or officers 2025-03-19
- 8-K Delisting / transfer of listing; Regulation FD disclosure; Financial statements and exhibits 2025-03-07
- 8-K Delisting / transfer of listing; Other material event; Financial statements and exhibits 2024-12-17
- SC 13D/A Amended activist ownership disclosure 2024-11-18
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for VCNX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open VCNX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.